DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$4.66M, compared with -$2.27M a year earlier.
Context
- Net debt amounted to 8.8% of total assets at the end of Q1 FY2026, up 2.9 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -104.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (15.41M) USD
- Year-over-year change
- -473.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.41M) | -473.8% |
| FY2024 | 2024-12-31 | (2.69M) | +35.2% |
| FY2023 | 2023-12-31 | (4.14M) | +2.7% |
| FY2022 | 2022-12-31 | (4.26M) | +8.5% |
| FY2021 | 2021-12-31 | (4.66M) | — |
Net Debt vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 net debt of -$4.66M is the highest of the 7 companies compared; the peer median is -$143.85M.
- Its year-over-year change of -104.8% is the 6th highest of 7, against a peer median of -43.9%.
- Net debt amounts to 8.8% of total assets for DMAC, versus a peer median of 37.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$4.66M | -104.8% | — | 8.8% | |
| Mar 2026 | -$36.43M | -91.0% | — | 56.6% | |
| Mar 2026 | -$98.11M | -3.9% | — | 33.5% | |
| Mar 2026 | -$137.54M | +48.8% | — | 32.8% | |
| Mar 2026 | -$150.15M | -153.5% | +50.0% | 41.4% | |
| Jun 2026 | -$174.03M | -83.9% | — | 15.0% | |
BIOABioAge Labs, Inc. | Mar 2026 | -$237.74M | +3.8% | — | 59.8% |
| Peer median (excluding DMAC) | -$143.85M | -43.9% | +50.0% | 37.5% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.